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Purpose: Primary open angle glaucoma (POAG) is the most common type of glaucoma. Among the POAG genes
identified so far, myocilin (MYOC) is the most frequently mutated gene in POAG patients worldwide. The MYOC
Gln48His mutation is unique among Indian POAG patients. This mutation has not been observed in some populations
within India and in other populations worldwide. The objectives of this work were to characterize and compare the mutation
spectrum among POAG patients from two places of South India and identify the occurrence and prevalence of Gln48His
mutation in our study populations.
Methods: One hundred-one (101) POAG patients from Chennai, South India were recruited for the study. Earlier, 100
patients from the southernmost part of India,  Kanyakumari district, were screened. MYOC was screened by polymerase
chain reaction based single stand conformation polymorphism (PCR-SSCP) methodology. DNA sequencing of deviant
samples was performed. Secondary structures of the proteins with amino acid sequence variations were predicted.
Results: The mutation frequency of MYOC among POAG patients in Chennai was 2%. Three types of mutations were
observed. The MYOC Gln48His mutation was observed among 2 POAG patients from Chennai. However, absence of this
mutation among patients from Kanyakumari suggests possible involvement of demographic factors in disease causation
via this mutation. Two heterozygous sequence variants, Thr353Ile and Asn480Lys, in the same exon (exon III) of
MYOC were observed in one POAG patient who had a severe disease phenotype. This is the first such report of a compound
heterozygote individual with two mutations in the same exon of MYOC.
Conclusions: The presence of mutations at a rate similar to other studies suggests the causative role of MYOC among
POAG patients from Chennai. Screening of more patients and families from all parts of India is required to identify the
actual frequency of the Gln48His mutation and thus highlight its importance. The compound heterozygote with a severe
disease phenotype reiterates the importance of MYOC in certain POAG patients.
Glaucoma is defined as progressive optic neuropathy that
results in irreversible visual field loss [1,2]. Glaucoma is the
second leading cause of blindness in the world [3]. Primary
open angle glaucoma (POAG) is the most common type of
glaucoma, affecting almost 2% of the world’s population [4].
India has a high prevalence of glaucoma with POAG being
the most common type [5]. The prevalence of POAG in south
Indian populations is about 1.6% [6,7] which is similar to that
observed in Western populations.
Among the various risk factors, a positive family history
of POAG is considered a major risk factor. Approximately,
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16%–22% of first degree relatives of POAG patients develop
the disease [8,9]. POAG is a complex heterogeneous disease
from the number of loci, genes, and mutations involved. A
recent review [10] lists 14 chromosomal loci for POAG as per
HUGO (Human Genome Organization) [11-18]. Mutations in
three genes namely, myocilin (MYOC, earlier called as the
TIGR-  Trabecular  meshwork  Inducible  Glucocorticoid
Response gene), optineurin (OPTN), and W (tryptophan) D
(aspartic acid) repeat 36 (WDR36) have been identified among
POAG patients [19-24]. Polymorphisms in cytochrome P450
1B1 (CYP1B1) [25,26] and heat shock protein 70-1 (HSP
70-1)  [27]  have  been  reported  among  POAG  patients.
Recently, the tumor protein 53 (p53) codon 72 polymorphism
(variant rs1042522) was suggested to be an increased risk
factor for POAG in Caucasians [28], while another study from
Turkey  did  not  find  such  an  association  [29].  Opticin
(OPTC) as a possible candidate gene for POAG has been
suggested [30].
Stone et al. [19] were the first to report mutations in
MYOC among POAG patients. Since then, many sequence
alterations  have  been  reported  in  MYOC  among  POAG
patients, worldwide [31-45]. Mutations in MYOC have been
observed in the juvenile and adult onset forms of POAG.
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3243Mutations have also been reported among both familial and
sporadic cases of POAG [19]. A few variants are recurrent in
various populations world-wide while some mutations were
observed to be ethnicity specific [46].
Mutation screening of a gene is normally performed for
2 reasons: a) to implicate the gene as a cause of a particular
disease, and b) to identify as many mutations as possible for
the  purpose  of  understanding  the  genotype-  phenotype
relationships. It can be used to compare mutation profiles
among different populations and for constructing practical
genetic tests for clinical use [34]. Further, discovery of the
range of mutation types and their locations may shed more
light on the little known normal function of myocilin protein
[47] and could contribute to the rapidly accruing knowledge
on the pathogenic roles of MYOC in causation of POAG [2,
47-49].  Identification  of  a  specific  mutation  or  mutations
responsible for a patient’s disease will solidify diagnosis and
may help predict clinical course of the disease [47].
An  average  mutation  frequency  of  ~1.4  –  4.6%  in
MYOC among POAG subjects [4,32,35,38] has been reported
from around the world. In studies on Indian patients, MYOC
mutations have been observed at a frequency of ~7.1% [50],
and 2% [51-53]. Most of the mutations (90%) have been
observed to be present on exon III of MYOC [46,54]. The
importance of exon I was highlighted by the observation of
the  Arg46Stop  mutation  which  is  second  most  common
mutation,  after  Gln368Stop  mutation.  The  Arg46Stop
mutation has been reported only among Asians [46]. The
importance of the exon I of MYOC among Indian POAG
patients is evident due to the Gln48His variant. As of date the
Gln48His has been reported only among POAG patients from
India [50,52,55] and not from any other part of the world.
The Gln48His mutation has been reported among patients
from Chennai (South India), Bangalore (South India), and
Kolkata (Eastern India) [46,51,56]. However, this mutation
was absent in patients from farther South of Chennai [49]. We
also did not observe the Gln48His mutation in our mutation
analysis  of  patients  from  Kanyakumari  district  (KK  dist),
South of Chennai [53]. We extended our mutation analysis to
include POAG patients from Chennai to compare the mutation
types and frequencies among the two places of South India.
METHODS
Clinical samples: The institutional human ethical committee
of  Dr.  ALMPGIBMS,  University  of  Madras,  Taramani
Campus,  Chennai,  India,  approved  the  study  pattern.
Informed consent was obtained from each individual before
blood was drawn. One hundred patients from Kanyakumari
district [53], and 101 patients from Chennai, diagnosed to
have  adult/juvenile-onset  primary  open  angle  glaucoma
(JOAG) were recruited for the study. Among the 101 patients
from Chennai, one of them (sample code; BSR-16) was a
JOAG  patient,  native  of  Kolkata  (eastern  India),  but  was
residing  in  Chennai.  Among  the  100  patients  (native  of
Chennai), eighty seven were adult onset POAG and 13 were
JOAG patients. Twenty two of the patients had at least one
family member affected by POAG. In two cases the family
history of the disease could not be confirmed. The patient,
BSR-16, was included in the present study because of the early
age of onset and severity of the disease. The patient also had
a family history of the disease. Equal number of age, sex, and
location matched controls were included in the study. Mean
age of patients (n=201) at sample collection was 58.6±13.5
(mean±SD)  years  (Chennai-  59.8±14  years;  KK  district-
57.4±13.3  years),  while  that  of  controls  (n=201;
Chennai=101;  KK  district=100)  was  58.9±14.4  years
(Chennai-  60±14.8  years;  KK  district-  57.8±14.2  years).
Among the individuals, 62.7% were males (Chennai- 70.3%;
KK  district-  55%)  both  among  patients  and  controls.
Proportion of male to female POAG patients were different
when compared between Chennai (71 males, 30 females) and
KK dist (55 males, 45 females); p=0.029 (Fisher’s exact test
using GraphPad Prism version 5 for Windows; GraphPad
Software, San Diego, CA). There were no other significant
differences.
A complete ophthalmic examination which consisted of
measurement of IOP, gonioscopic evaluation of the angle,
examination and documentation of the optic disc, and the
visual  field  (VF)  testing  was  performed  by  certified
ophthalmologists.  Visual  field  testing  was  done  using
Humphreys  automated  field  analyzer  and/or  Bjerrum’s
tangent  screen  manual  kinetic  perimetry.  Three  or  more
contiguously  missed  points  on  automated  perimetry  tests
(repeatedly) were taken as a VF defect [57]. Visual field
examinations using Bjerrum’s (Tangent) screen, grading and
reporting  of  the  results  were  conducted  by  certified  and
experienced ophthalmologists. Localized arcuate area defects
or greater, consistent with glaucomatous cupping and no other
identifiable cause for the same were regarded as glaucomatous
VF defects. The criteria for diagnosing glaucoma were based
on earlier reports [53,58]. Classification of adult and juvenile
types of POAG was based on the age of disease onset being
≥40 years or <40 years of age, respectively [2,58,59].
Analysis of MYOC: Genomic DNA was isolated from the
blood samples of patients and controls using the salting out
method of Miller et al. [60] Eight primer sets (Table 1) were
designed to amplify MYOC in fragments of <300 bp [53] for
single strand conformation polymorphism (SSCP) analysis.
PCR amplifications were performed in 20 µl reaction volumes
containing ~100 ng of genomic DNA, 5 pmol of forward and
reverse primers, 2 mM of each dNTP, 0.5 U of Taq polymerase
with  a  standard  buffer  containing  1.5  mM  MgCl2.
Amplification was performed as per the conditions mentioned
previously  [53].  Briefly,  these  conditions  include  initial
denaturation at 94 °C for 5 min, followed by 30 cycles of
denaturation (94 °C, 30 s), annealing (primer pair dependent
Molecular Vision 2011; 17:3243-3253 <http://www.molvis.org/molvis/v17/a349> © 2011 Molecular Vision
3244temperature - Table 1, 30 s), and extension (72 °C, 30 s) each,
followed by a final extension of 2 min at 72 °C.
The amplicon products were mixed with the loading dye
(bromophenol  blue  +  xylene  cyanol  +  formamide  +
Na2EDTA) and double distilled water in the following ratio
(2 μl + 2 μl + 16 μl; amplicon + dye + dd water), heat denatured
for 5 min in boiling water and electrophoresed on a composite
(acrylamide, bis acrylamide + agarose) gel [61] for 13 to 14
h. The percentage of the gels used and the electrophoresis
voltage varied for amplicons of the different primers sets. Gels
were silver stained as per the protocol of Bassam et al. [62]
The amplicons with a mobility shift were reamplified, column
purified and sequenced using dye termination chemistry and
read using the 96 capillary 3730x1 DNA analyzer (Applied
Biosystems, Carlsbad, CA). Sequences were analyzed using
BLAST to identify the variation(s).
The DNA sequences with a variation were translated in
silico to obtain the corresponding amino acid sequences. The
amino  acid  sequences  were  subjected  to  the  secondary
structure prediction using the Garnier Osguthorpe Robson
(GOR)  prediction  method  [63,64].  Further,  motifs  and
modifications  sites  were  predicted  using  PROSITE  and
MotifScan.
RESULTS
A total of five different mutations and two polymorphisms
were  observed  among  patients  from  Kanyakumari  district
[53], and Chennai (Table 2). All the sequence changes have
been submitted to dbSNP and accession numbers included in
Table  2.  There  were  no  significant  differences  (p>0.05)
between various cohorts with mutations versus those without
mutations  using  Fisher’s  exact  test  (contingency  table
analysis, GraphPad Prism version 5). Some of the cohort
comparisons are listed below;
1. Total number of patients with mutations (5 of
201) versus number of controls with mutations (0 of
201); p=0.06;
TABLE 1. PRIMER SEQUENCES USED TO AMPLIFY THE MYOC GENE IN FRAGMENTS OF <300 BASE PAIRS ALONG WITH PRIMER NAME,
ANNEALING TEMPERATURE (TA) FOR EACH PRIMER PAIR AND THE EXPECTED PRODUCT SIZE.
Primer name Sequence Ta (degree
Celsius)
Product Size
(base pairs)
RR3 Forward-5’-TGGATTAAGTGGTGCTTC-3' 58 227
RR4 Reverse-5’-TGGCTGATGAGGTCATAC-3’    
RR5 Forward-5’-GGATGTCCGCCAGGTTT-3’ 60 260
RR6 Reverse-5’-CAATGTCCGTGTAGCCAC-3’    
RR7 Forward-5’-TGGCTACCACGGACAGTT-3’ 62 243
RR8 Reverse-5’-GAGGTGTAGCTGCTGAC-3’    
RR9 Forward-5’-CCTTCATCATCTGTGGCA-3’ 64 248
RR10 Reverse-5’-GTACAGCTTGGAGGCTT-3’    
RR1 Forward-5’-AGAGCTTTCCAGAGGAAG-3’ 64 248
RR2 Reverse-5’-ATGACTGACATGGCCTGG-3’    
RR11 Forward-5’-GTCCCAATGAATCCAGCT-3’ 62 268
RR12 Reverse-5’-TTGCTGTAGGCAGTCTCC-3’    
RR13 Forward-5’-GACCAGCTGGAAACCCA-3’ 60 256
RR14 Reverse-5’-TGCTGAACTCAGAGTCC-3’    
RR15 Forward-5’-CATAGTCAATCCTTGGGC-3’ 64 231
RR16 Reverse-5’-TAAAGACCACGTGGGCAC-3’    
TABLE 2. COMPARISON OF MYOC GENE MUTATIONS AND POLYMORPHISMS (WITH DBSNP ACCESSION NUMBERS) OBSERVED AMONG POAG PATIENTS FROM CHENNAI AND  K$NYAKUMARI
DISTRICT OF SOUTH INDIA.
   
Mutations Polymorphisms
Location Group Gln48His
ss295476454
Ser331Thr
ss295476451
Thr353Ile
ss295476455
Pro370Leu
ss295476453
Asn480Lys
ss295476456
Thr325Thr
ss295476450
Try347tyr
ss295476452
Chennai Patients
n=101
2 0 1 0 1 0 0
  Controls
n=101
0 0 0 0 0 0 0
KK
District
Patients
n=100
0 1 0 1 0 1 4
  Controls
n=100
0 0 0 0 0 0 0
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32452. JOAG patients with mutations (2/27; including
subject BSR-16) versus adult onset POAG patients
with mutations (3/174), p=0.13;
3. Male  patients  with  mutations  (3/126)  versus
female patients with mutations (2/75), p=1;
4. Number  of  mutant  Chennai  patients  (2/100;
excluding subject BSR-16, not native of Chennai)
versus number of mutant KK dist patients (2/100);
p=1;
5. Chennai  patients  with  mutations  (2/100;
excluding BSR-16, not native of Chennai) versus
Chennai controls with mutations (0/101), p=0.24;
6. KK dist patients with mutations (2/100) versus
KK dist controls with mutations (0/100), p=0.49.
All  mutations  observed  among  patients  were  in  the
heterozygous state and were absent in controls. Two different
mutations,  Pro370Leu  and  Ser331Thr,  were  observed  in
patients from Kanyakumari district, of which Ser331Thr was
a  novel  variant.  These  two  mutations,  Pro370Leu  and
Ser331Thr, have been reported and discussed earlier [53] and
hence are not discussed here. Three different mutations were
observed among the 101 patients from Chennai.
MYOC Gln48His: Two patients from Chennai (Sample
Codes; Eg-17 and Eg-10) had the Gln48His variation (Figure
1). The Gln48His variation is a 144 G>T transversion which
resulted  in  a  non-conservative  amino  acid  substitution,
glutamine (Gln) to histidine (His). Presence of this mutation
in patients and absence in controls indicates that this variant
might play a disease causative role.
Age of onset of glaucoma was at 63 years for patient
Eg-17. He had raised intraocular pressures and glaucomatous
optic  neuropathy  (Table  3).  Visual  field  tests  revealed
constricted fields in the right eye and tubular vision in the left
eye. The patient was under medication - Iobet 0.5%. The
patient Eg-10 had been diagnosed for POAG a year earlier
(age of onset, 43). The patient had a raised IOP and increased
cup/disc ratio in the right eye. The patient had an enlarged
Blind Spot (BS) in the left eye and ≤35° vision in the right
eye. The pressures were reduced to normal levels, 17.4 (OD)/
7.2 (OS) mmHg after medication (Iobet 0.5%).
The other patient with mutations (BSR-16, from Kolkata)
turned out to be a compound heterozygote. Two mutations,
Thr353Ile and Asn480Lys, both in the heterozygous state
were observed in exon III of MYOC.
MYOC Thr353Ile: This mutation is a heterozygous C>T
transition in nucleotide 1058 (Figure 2A) which resulted in a
threonine  to  isoleucine  change.  This  results  in  change  in
polarity. This has been reported earlier among POAG patients
and control subjects from Asia [4]. However in our study this
was not observed in controls.
MYOC  Asn480Lys:  This  mutation,  asparagine  (polar
amino acid) to lysine (positively charged amino acid), is a
result of a heterozygous C>A transversion at nucleotide 1440
(Figure  2B).  This  variant  has  been  reported  from  other
populations [31]. Founder effect for this mutation has also
been reported [31].
The patient BSR-16 had an early age of onset of the
disease (diagnosed at age 14). She had rapid progression of
the disease and before POAG could be diagnosed and treated
(trabeculectomy) she had lost the vision of her left eye and
had a considerable vision loss in the right eye. She had been
diagnosed  and  treated  elsewhere  initially,  before  finally
visiting one of the hospitals involved in the present study. The
pressure in her right eye during the blood collection was
21 mmHg. The optic cup/disc ratio was 0.9 in the right eye
with a totally excavated disc in the left eye (Table 3). The
patient was blind in the left eye and had ~25° vision in the
right eye (Figure 3). A positive family history of POAG was
recorded based on the patient’s information.
Secondary  structure  prediction  using  GOR  showed
changes  in  the  predicted  structure  among  all  the  mutant
protein  sequences.  Further,  other  tools  to  predict  the
modification sites namely PROSITE and MotifScan identified
the presence of motifs/ modifications sites possibly being
affected as a result of these secondary structural changes. The
effects  of  the  mutations  based  on  the  prediction  using
softwares have been shown in Table 4.
Figure  1.  Heterozygous  Gln48His
mutation  in  MYOC.  Chromatogram
sequence  derived  from  patient  Eg-10
with the G>T transversion (indicated by
arrow) compared to the normal control.
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3247Sequencing of 10 random samples using each primer set
confirmed the results of SSCP analysis.
DISCUSSION
The mutation frequency in MYOC among POAG patients in
this  study  was  2.48%.  The  mutation  frequency  observed
among patients from Chennai was 2% (2 of 100; excluding
the patient BSR-16 who originated from Kolkata, eastern part
of India). A similar mutation frequency of 2% among POAG
patients from kanyakumari district was reported earlier [53].
These  observed  mutation  frequencies  are  similar  to  those
reported from other populations in India [39,50,52,53] and
rest of the world [4,38].
The presence of the MYOC Gln48His mutation among
POAG patients from Chennai at a frequency of 2% conforms
to earlier reports [39,52] and reiterates the importance and
possible disease causing role of MYOC, especially exon I,
among Indian POAG patients. The MYOC mutation frequency
was much higher, 5.35% (3/56), in a study on POAG patients
from Kolkata (eastern part of India) [50]. The frequency was
lower at 0.8% in a study on patients from a different part of
South  India  [56].  The  Gln48His  mutation  has  not  been
reported from any other population in the world so far.
Among patients from the KK district (the southern-most
part of India) the Gln48His mutation was not observed [53].
In an earlier study by Kanagavalli et al. [51] the Gln48His
mutation was not observed among patients from Madurai
(farther south of Chennai and closer to the KK district). This
suggests the possible involvement of demographic factors in
causation of POAG (via the Gln48His mutation). Further,
there are no reports of this variant being present in families.
Inconsistency in the presence/absence of Gln48His and its
prevalence  among  different  populations  in  India  makes  it
difficult to comprehend its role in disease causation.
It is essential to screen more patients from South India to
confirm or rule out association of the Gln48His mutation with
demographic  factors.  A  proper  mutation  frequency  is  a
prerequisite to initiate the screening of such region-specific
mutations as a clinical diagnostic tool. Thus screening of
Figure  2.  Chromatograms  depicting
MYOC  gene  sequence  changes  in  a
compound heterozygote POAG patient
from India. A: Heterozygous The353Ile
mutation  in  MYOC.  Chromatogram
sequence derived from patient BSR-16
with the C>T transition (indicated by
arrow) compared to the normal control.
B: Heterozygous Asn480Lys mutation
in  MYOC.  Chromatogram  sequence
derived from patient BSR-16 with the
C>A transversion (indicated by arrow)
compared to the normal control.
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3248Gln48His among POAG patients from other parts of India is
also essential to establish it as a potential diagnostic tool for
this part of the world. Since the Gln48His mutations have not
been  reported  in  familial  cases  from  India,  families  with
POAG must also be screened thoroughly to rule out or confirm
the involvement of this mutation in familial cases.
Predictions using bioinformatics’ tools revealed changes
in the secondary structure of the Gln48His mutant protein
close to a putative phosphorylation (PKC) site at amino acids
44–46. Further, the cysteine at the 47th amino acid has been
proposed to be involved in oligomerization of myocilin [65].
The  predicted  secondary  structural  changes  due  to  the
Gln48His  mutation  could  hinder  oligomerization  via  the
cysteine  residue  (47th  amino  acid)  thereby  resulting  in
aberrant functioning of the protein. Functional studies are
required to deduce the actual effect of the Gln48His mutation.
In this study two sequence variants in the same exon
(exon III) of MYOC were observed in a POAG patient. The
patient was a native of Kolkata (eastern part of India). The
mutation frequency of MYOC is high among POAG patients
of the eastern part of India [50]. Our study is the first report
of a compound heterozygote with two mutations in the same
exon (exon III) of MYOC. The occurrence of two variants
(both resulting in amino acid changes) in different exons of
the MYOC gene has been reported earlier [36] wherein the
individual had a severe phenotype including an aggressive
form of POAG and an early age of onset (14 years of age).
The  individual  had  a  disease  causing  variation  namely
Lys423Glu (familial), and the Arg126Trp in exon I which had
Figure 3. Humphreys visual field chart
showing the visual field damage in the
right  eye  of  patient  BSR-16,  a
compound  heterozygote  with  two
mutations in exon III of MYOC.
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3249been  observed  in  controls  as  well  [36].  Two  compound
heterozygote POAG patients for the CYP1B1 gene have been
reported in one study [56].
Similar  to  the  Arg126Trp  in  the  earlier  reported
compound heterozygote [36], the Thr353Ile has been reported
in controls [4] though not in our study and has been associated
with  an  intermediate  disease  phenotype  [4,66].  The  other
mutation Asn480Lys in our compound heterozygote has been
reported in other studies as well and has also been associated
with an intermediate disease phenotype [67,68]. Further, the
Asn480Lys  mutation  has  earlier  been  reported  to  be
associated  with  families  and  to  have  a  founder  effect,
(reviewed by Gong et al. [46]).
The compound heterozygote individual, BSR-16, had a
positive family history and a severe disease phenotype. The
patient, BSR-16, had an early age of disease onset (14 years
of  age)  and  aggressive  form  of  the  disease  with  rapid
progression which was comparable to that reported earlier
[36]. Efforts to screen the family for mutations proved futile
as the members were not approachable (in terms of location
and other factors) for blood samples. Presence of two variants
in the same individual and the presence of a severe phenotype
suggest a combinatorial role of the two variations in disease
causation. This observation in the Kolkata patient, along with
the earlier report of a high mutation frequency in MYOC of
POAG  patients  from  Kolkata  [50],  indicate  the  stronger
association of MYOC with POAG in the eastern part of India
compared with the other parts.
An early age of disease onset and rapid progression of the
disease  has  also  been  observed  in  some  patients  with  an
apparently normal MYOC gene. These observations indicate
the  possible  role  of  other  genes  in  causation  of  POAG.
However, in the case of patient BSR-16, the combinatorial
effect of the 2 mutations cannot be ruled out. Both variants
had either a predicted alteration of protein secondary structure
that  overlapped  a  putative  phosphorylation  (CK2)  site  or
predicted alteration of a phosphorylation (PKC) site (Table 4).
Functional analyses of the mutant proteins are essential to
confirm  the  importance  of  these  predicted  alterations  in
putative modification sites or changes in secondary structure
altering overlapping/ nearby motifs or modification sites.
Mutations in presently known genes account for only a
low percentage of all POAG cases (less than 10%) [29]. About
5% of POAG is caused by mutations in myocilin or optineurin
[47]. Hence, more extensive genetic studies are required to
identify other genes involved and to understand the molecular
mechanisms of the disease. Most cases of primary open angle
glaucoma are complex and multi-factorial [47], hence the role
of epigenetic processes such as DNA methylation and histone
modifications along with small interfering RNA cannot be
ruled out and have to be addressed to better understand the
complete mechanism of disease onset and prognosis.
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